Supermediastinoscopies: A Step Forward in Lung Cancer Staging  by Rami-Porta, Ramón
MINI-SYMPOSIUM ON EMERGING TECHNIQUES FOR LUNG CANCER STAGING
Supermediastinoscopies: A Step Forward in Lung
Cancer Staging
Ramo´n Rami-Porta, MD, Guest Editor
(J Thorac Oncol. 2007;2: 355–356)
Clinical staging of lung cancer can be performed withdifferent degrees of certainty. Sophisticated imaging
techniques will better define the anatomical extension of the
tumor compared with medical history, physical examination,
and simple radiographic images. However, the highest cer-
tainty will be achieved using techniques that provide tissue
confirmation of the anatomical extension of lung cancer into
regional lymph nodes or adjacent structures. The Union Inter-
nationale Contre le Cancer recommends the use of the certainty
(C) factor, which is an optional descriptor of the tumor, node,
metastasis (TNM) classification that reflects the validity of
classification according to the methods used (Table 1).1
The articles included in the mini-symposium of this issue
aim at highest certainty in clinical staging of lung cancer,
especially regarding nodal spread. In their article, De Leyn et al.2
summarize 2 years’ work undertaken by members of the Euro-
pean Society of Thoracic Surgeons who met in different work-
shops to review evidence on clinical, intraoperative, and patho-
logical staging of non-small cell lung cancer. The resulting
guidelines clearly show that the trend in Europe is toward
avoiding approximation and aiming at the highest possible
certainty. This implies tissue confirmation of regional nodal
spread, except in a very selected group of patients with unusu-
ally small, peripheral squamous cell carcinomas with no evi-
dence of nodal involvement on imaging or metabolic studies.
Tissue confirmation also applies to restaging after induction
treatment, when it is so important to assess objective response
and rule out residual nodal disease to indicate further treatment.
The European guidelines favor a thorough intraoperative nodal
assessment and recommend systematic nodal dissection as the
best way to evaluate hilar and mediastinal nodal spread. Both
clinical and pathological staging have to be supported by an
intense pathological study of the removed specimens: adequate
specimen sampling and precise description of nodal involve-
ment will complete the staging process and add to its certainty.
The following four articles of the mini-symposium
deal with variations of mediastinoscopy. In their own way,
mediastinoscopic ultrasonography (MUS),3 remediastinos-
copy,4 video-assisted mediastinoscopic lymphadenectomy
(VAMLA),5 and transcervical extended mediastinal lymphade-
nectomy (TEMLA)6 are supermediastinoscopies that aim to
improve the diagnostic accuracy of standard cervical medi-
astinoscopy.
Ultrasonography probes have been put into the pleural
and abdominal cavities to identify small lung nodules and to
assess liver metastases. It was a matter of time before they
made it into the mediastinum. In their article, Hu¨rtgen et al.3
show how accurate MUS can be in ruling out direct medias-
tinal involvement by the primary lung cancer. In their series
of 14 patients with cT4 tumors assessed by computed tomog-
raphy who underwent resection, they found that none of them
in fact had T4 tumors, and the correlation of MUS assessment
and pathological staging after surgical intervention was al-
most perfect. Only one tumor was misclassified by MUS, but
it was a T3 tumor, not a T4. Additionally, MUS predicted
resectability in four additional patients who underwent tho-
racotomy but whose tumors were not resected because of
functional or oncological reasons. MUS is a good example of
how a combination of techniques (ultrasonography indicated
on the basis of computed tomography findings and guided by
mediastinoscopy) improves clinical staging.
Remediastinoscopy is a challenging operation that only
experienced and dedicated surgeons enjoy performing, and
they obtain the maximal yield from it. It is, indeed, a super-
mediastinoscopy: it demands skill, patience, and the convic-
tion that the surgeon is doing something useful for the patient.
In the era of induction therapy for locally advanced lung
cancer, especially N2 disease, the persistence of mediastinal
nodal involvement after induction has proved to be an omi-
nous prognostic factor. Based on their own experience and on
published reports on the subject, Van Schil et al.4 show that
remediastinoscopy is technically feasible, is no longer a
contraindication for the established indications, and is more
accurate than imaging studies when performed to assess
tumor response after induction therapy. Remediastinoscopy
for this indication also has prognostic relevance because it
selects patients who will benefit most from lung resection.
The authors are well aware that remediastinoscopy will be
difficult to generalize because of its intrinsic technical diffi-
culties because of peritracheal adhesions. They point out that
both endobronchial and esophageal ultrasound-guided fine
needle aspiration can be used for staging, reserving medias-
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tinoscopy for restaging. Both endoscopic techniques have
also been used for restaging, with sensitivity and diagnostic
accuracy values very similar to those of remediastinoscopy.7,8
There is no doubt that the integration of these endoscopic
techniques into the staging and restaging algorithms would
make the whole process simpler with only a little loss of
information provided by the more thorough exploration de-
rived from surgical procedures. This integration is clearly
favored by the European guidelines on staging and restaging.2
The last two articles of the mini-symposium deal with
fascinating techniques, the objective of which is to perform
mediastinal lymphadenectomy through the cervical inci-
sion used for mediastinoscopy. VAMLA5 is a totally en-
doscopic technique performed through a video-mediasti-
noscope. TEMLA6 is a mainly open procedure assisted
with the video-mediastinoscope or video-thoracoscope at
certain steps of the operation, i.e., when dissecting the
subcarinal space or the subaortic region. With VAMLA,
the nodal stations of the superior mediastinum, including
right and left paratracheal and subcarinal nodes, are removed.
The resection performed with TEMLA is more extensive
because it also includes the highest mediastinal nodes, the
subaortic and anterior mediastinal stations, and the para-
esophageal nodes. Neither VAMLA nor TEMLA is indicated
as the first staging procedure when there is evident medias-
tinal involvement, in which case endoscopic procedures with
fine needle aspiration would be the first choice. An important
aspect of these techniques is that they remove all the lymph
nodes of the explored nodal stations, thus facilitating the
identification of minimal nodal disease that is not identified
on computed tomography or positron emission tomography
and that escapes standard mediastinoscopy. This complete
removal is an advantage but, at the same time, poses an
important problem: for patients with N2 disease diagnosed by
VAMLA or TEMLA who receive induction therapy, there are
no nodes left to assess objective tumor response and down-
staging. We know that nodal status after induction is an
important prognostic factor, but for patients undergoing
VAMLA and TEMLA, nodal restaging is not possible be-
cause there is no material left for a new biopsy. New param-
eters of tumor response based on the T component of the
TNM classification or on biologic factors will have to be
determined to indicate further therapy after induction.
VAMLA and TEMLA could also be considered part of the
induction treatment because, for patients with mediastinal
nodal disease, the tumor is both staged and down-staged by
the operations. One is tempted to think that, in this circum-
stance, if there has been no progressive disease during induc-
tion therapy, the patient deserves to be offered the benefit of
resection, especially when the intraoperative pathologic study
of the remaining lymph node specimen removed at thoracot-
omy confirms the absence of nodal involvement, and the
required resection is a lobectomy.
Fifty years after Carlens performed his first mediasti-
noscopy, technical improvements have allowed the develop-
ment of the procedure to such an extent that it barely resem-
bles the original one. European thoracic surgeons are for the
highest staging certainty, and this implies the use of medias-
tinoscopy. Remediastinoscopy has already meant a change in
paradigms, allowing the selective indication of lung resection
after induction therapy. It is not difficult to envisage new
paradigm changes in clinical practice based on the results of
VAMLA and TEMLA. Professionals involved in the care of
patients with lung cancer should have their minds open to
absorb all these changes and make the best use of them.
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TABLE 1. Certainty (C) Factor and Its Applicability
Factor Description of Staging Methods Applicability
C1 Evidence from standard diagnostic means (e.g., inspection, palpation, and standard radiography,
intraluminal endoscopy for tumors of certain organs)
C2 Evidence obtained by special diagnostic means (e.g., radiographic imaging in special projections,
tomography, computed tomography, ultrasonography, lymphography, angiography,
scintigraphy, magnetic resonance imaging, positron emission tomography, endoscopy, biopsy,
and cytology)
cTNM, rTNM, and ycTNM
C3 Evidence from surgical exploration, including biopsy and cytology
C4 Evidence of the extent of the disease after definitive surgery and pathologic examination of the
resected specimen
pTNM and ypTNM
C5 Evidence from autopsy aTNM
cTNM, clinical tumor, node, metastasis classification; rTNM, pretreatment classification of recurrent tumors; ycTNM, classification after induction therapy before definitive
treatment; pTNM, pathological classification; ypTNM, pathological classification after induction therapy; aTNM, autopsy classification.
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